Study #2026-0165
ELA026-CP003: A Study Of ELA026 In Participants With Relapsed/Refractory T/NK-Cell Malignancies (TCM)
MD Anderson Study Status
Enrolling
Treatment Agent
ELA026
Description
This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
T Cell Malignancies
Study phase:
Phase I
Physician name:
Swaminathan Iyer
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.